Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding studyReportar como inadecuado




Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 12:296

First Online: 18 July 2012Received: 11 January 2012Accepted: 20 June 2012DOI: 10.1186-1471-2407-12-296

Cite this article as: Minami, S., Kijima, T., Takahashi, R. et al. BMC Cancer 2012 12: 296. doi:10.1186-1471-2407-12-296

Abstract

BackgroundErlotinib and pemetrexed have been approved for the second-line treatment of non-small cell lung cancer NSCLC. These two agents have different mechanisms of action. Combined treatment with erlotinib and pemetrexed could potentially augment the antitumor activity of either agent alone. In the present study, we investigated the safety profile of combined administration of the two agents in pretreated NSCLC patients.

MethodsA phase I dose-finding study Trial registration: UMIN000002900 was performed in patients with stage III-IV nonsquamous NSCLC whose disease had progressed on or after receiving first-line chemotherapy. Patients received 500 mg-m of pemetrexed intravenously every 21 days and erlotinib 100 mg at Level 1 and 150 mg at Level 2 orally on days 2–16.

ResultsTwelve patients, nine males and three females, were recruited. Patient characteristics included a median age of 66 years range, 48–78 years, stage IV disease nine cases, adenocarcinoma seven cases and activating mutation-positives in the epidermal growth factor receptor gene two cases. Treatment was well-tolerated, and the recommended dose of erlotinib was fixed at 150 mg. Dose-limiting toxicities were experienced in three patients and included: grade 3 elevation of serum alanine aminotransferase, repetitive grade 4 neutropenia that required reduction of the second dose of pemetrexed and grade 3 diarrhea. No patient experienced drug-induced interstitial lung disease. Three patients achieved a partial response and stable disease was maintained in five patients.

ConclusionsCombination chemotherapy of intermittent erlotinib with pemetrexed was well-tolerated, with promising efficacy against pretreated advanced nonsquamous NSCLC.

KeywordsCombination Erlotinib Pemetrexed NSCLC Phase I  Download fulltext PDF



Autor: Seigo Minami - Takashi Kijima - Ryo Takahashi - Hiroshi Kida - Takeshi Nakatani - Masanari Hamaguchi - Yoshiko Takeuchi - I

Fuente: https://link.springer.com/







Documentos relacionados